Pre-Annual General Meeting Information • Nov 6, 2008
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
Contact: SE-753 18 Uppsala Torben Jörgensen, President and CEO Tel+46 18 56 59 00 Tel: +46 707 49 05 84, [email protected] www.biotage.com
Kungsgatan 76
Uppsala November 6, 2008
Shareholders in Biotage AB are hereby invited to attend the Extraordinary General Meeting, to be held on Friday, November 21, 2008, at 10.00 a.m., at the head office of Biotage AB, Kungsgatan 76 in Uppsala, Sweden.
Shareholders who wish to participate in the Extraordinary General Meeting must a) be recorded as a shareholder in the share register maintained by VPC on Friday, November 14, 2008, and
b) notify the company of their intention to participate in the Extraordinary General Meeting, no later than Monday, November 17, 2008, at 4.00 p.m.
Notice of participation in the Extraordinary General Meeting may be made to the company by mail to the address Kungsgatan 76, SE-753 18 Uppsala, Sweden, by fax + 46-18-591922, or by e-mail: [email protected]. The notification should include the following information: name, social security number/corporate registration number, address, telephone number, shareholdings and number of accompanying assistants (maximum two).
Shareholders participating through a representative must provide a proxy for the representative. If the proxy is issued by a legal entity, a certified copy of the registration certificate for the legal entity must be enclosed. The proxy may not be older than one year. The proxy in the original and, where applicable, the registration certificate should be sent in due time prior to the Extraordinary General Meeting, to Biotage AB at the address Kungsgatan 76, 753 18 Uppsala, Sweden. A proxy form is available at www.biotage.com/proxy.
To be entitled to participate in the Extraordinary General Meeting, shareholders whose shares are nominee registered must temporarily have the shares ownerregistered with VPC. Shareholders who wish to make such re-registration must notify their nominee thereof. The re-registration must be made no later than on Friday, November 14, 2008, and the shareholders should in due time before such date notify the nominee thereof.
In the company there are in total 88,486,320 shares with one vote each.
Opening of the Extraordinary General Meeting and election of the Chairman.
Determination whether the Extraordinary General Meeting has been duly convened.
Resolution on reduction of statutory reserve.
Closing of the Extraordinary General Meeting.
With the objective to increase the company's financial flexibility, Biotage's Board of Directors proposes that the company's statutory reserve shall be reduced with an amount of SEK 842.180.000 by means of transfer of the aforesaid amount to a reserve to be used in accordance with resolution/s adopted at forthcoming General Meetings. The statutory reserve will be entirely dissolved following the execution of the said reduction. Approval by the Swedish Companies Registration Office (Sw. Bolagsverket), or the general court (Sw. allmän domstol) in case of a dispute, is required to effectuate the proposed reduction of statutory reserve.
Uppsala in November 2008 Biotage AB (publ) The Board of Directors
About Biotage
Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the area of medicinal chemistry. In 2005 business and products from the company Argonaut were acquired, further strengthening the product range in medicinal chemistry. The customers include the worlds top 30 pharma companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany and several other European countries. Biotage has 300 employees and had sales of SEK 496m in 2007. Biotage is listed on the OMX Nordic stock exchange. Website: www.biotage.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.